Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets
Joanna Kopecka, Patrick Trouillas, Ana Čipak Gašparović, et al.
Drug Resistance Updates (2019) Vol. 49, pp. 100670-100670
Open Access | Times Cited: 217

Showing 1-25 of 217 citing articles:

Tumour fatty acid metabolism in the context of therapy resistance and obesity
Andrew J. Hoy, Shilpa R. Nagarajan, Lisa M. Butler
Nature reviews. Cancer (2021) Vol. 21, Iss. 12, pp. 753-766
Closed Access | Times Cited: 259
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
Sabrina Dallavalle, Vladimir Dobričić, Loretta Lazzarato, et al.
Drug Resistance Updates (2020) Vol. 50, pp. 100682-100682
Open Access | Times Cited: 241
Lipid metabolism in cancer progression and therapeutic strategies
Yan Fu, Tiantian Zou, Xiaotian Shen, et al.
MedComm (2020) Vol. 2, Iss. 1, pp. 27-59
Open Access | Times Cited: 215
Enzymatic Noncovalent Synthesis
Hongjian He, Weiyi Tan, Jiaqi Guo, et al.
Chemical Reviews (2020) Vol. 120, Iss. 18, pp. 9994-10078
Open Access | Times Cited: 176
Hypoxia as a driver of resistance to immunotherapy
Joanna Kopecka, Iris C. Salaroglio, Elisabeth Pérez-Ruíz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100787-100787
Open Access | Times Cited: 174
Therapeutic strategies to overcome taxane resistance in cancer
Tuyelee Das, Uttpal Anand, Swaroop Kumar Pandey, et al.
Drug Resistance Updates (2021) Vol. 55, pp. 100754-100754
Closed Access | Times Cited: 156
Novel nanomedicines to overcome cancer multidrug resistance
Zhenwei Su, Shaowei Dong, Shan‐Chao Zhao, et al.
Drug Resistance Updates (2021) Vol. 58, pp. 100777-100777
Closed Access | Times Cited: 137
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics
Hao-Ran Jin, Jin Wang, Zijing Wang, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 135
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects
Maohua Huang, Yuning Lin, Chenran Wang, et al.
Drug Resistance Updates (2022) Vol. 64, pp. 100849-100849
Closed Access | Times Cited: 97
Long non-coding RNA mediated drug resistance in breast cancer
Deepshikha Singh, Yehuda G. Assaraf, Rajesh N. Gacche
Drug Resistance Updates (2022) Vol. 63, pp. 100851-100851
Closed Access | Times Cited: 96
Emerging therapies in cancer metabolism
Yi Xiao, Tian‐Jian Yu, Ying Xu, et al.
Cell Metabolism (2023) Vol. 35, Iss. 8, pp. 1283-1303
Open Access | Times Cited: 91
β-Sitosterol as a Promising Anticancer Agent for Chemoprevention and Chemotherapy: Mechanisms of Action and Future Prospects
Haoyu Wang, Zhi Wang, Zihui Zhang, et al.
Advances in Nutrition (2023) Vol. 14, Iss. 5, pp. 1085-1110
Open Access | Times Cited: 64
Accumulated cholesterol protects tumours from elevated lipid peroxidation in the microenvironment
Xi Zhao, Xinyu Lian, Jianlan Xie, et al.
Redox Biology (2023) Vol. 62, pp. 102678-102678
Open Access | Times Cited: 45
Helicobacter pylori infection: a dynamic process from diagnosis to treatment
Qifang Sun, Chengzhi Yuan, Sainan Zhou, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 44
Spatial Transcriptomic and Metabolomic Landscapes of Oral Submucous Fibrosis‐Derived Oral Squamous Cell Carcinoma and its Tumor Microenvironment
Yuan Zhi, Qian Wang, Moxin Zi, et al.
Advanced Science (2024) Vol. 11, Iss. 12
Open Access | Times Cited: 21
Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy
Andrea Nicolini, Paola Ferrari
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 18
Oxidative Stress and Reprogramming of Lipid Metabolism in Cancers
Siqi Li, Hang Yuan, Liang Li, et al.
Antioxidants (2025) Vol. 14, Iss. 2, pp. 201-201
Open Access | Times Cited: 3
New Insights Into Targeting Membrane Lipids for Cancer Therapy
Giulio Preta
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 97
Impact of cancer metabolism on therapy resistance – Clinical implications
Ana Cristina Gonçalves, Elena Richiardone, Joana Jorge, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100797-100797
Open Access | Times Cited: 89
Repurposing old drugs to fight multidrug resistant cancers
Jelena Dinić, Thomas Efferth, Alfonso T. García‐Sosa, et al.
Drug Resistance Updates (2020) Vol. 52, pp. 100713-100713
Open Access | Times Cited: 80
New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma
Michele Dal Bo, Elena De Mattia, Lorena Baboçi, et al.
Drug Resistance Updates (2020) Vol. 51, pp. 100702-100702
Open Access | Times Cited: 77
Chemotoxicity-induced exosomal lncFERO regulates ferroptosis and stemness in gastric cancer stem cells
Haiyang Zhang, Meng Wang, Yi He, et al.
Cell Death and Disease (2021) Vol. 12, Iss. 12
Open Access | Times Cited: 75
Inhibition of NPC1L1 disrupts adaptive responses of drug‐tolerant persister cells to chemotherapy
Zhe Zhang, Siyuan Qin, Yan Chen, et al.
EMBO Molecular Medicine (2022) Vol. 14, Iss. 2
Open Access | Times Cited: 69
DRESIS: the first comprehensive landscape of drug resistance information
Xiuna Sun, Yintao Zhang, Hanyang Li, et al.
Nucleic Acids Research (2022) Vol. 51, Iss. D1, pp. D1263-D1275
Open Access | Times Cited: 58
Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability
Giasemi C. Eptaminitaki, Dimitris Stellas, Benjamin Bonavida, et al.
Drug Resistance Updates (2022) Vol. 65, pp. 100866-100866
Closed Access | Times Cited: 51
Page 1 - Next Page

Scroll to top